American BriVision (Holding) Corporation 是一間臨床階段生物製藥公司,致力開發藥物及醫療器械,以滿足美國尚未滿足的醫療需求。
財務指標
營業收入
2026-06-30
$0
2026-03-31
$0
2025-12-31
-$795.95K
2025-09-30
$795.95K
營業支出
2026-06-30
$779.52K
2026-03-31
$1.57M
2025-12-31
$2.19M
2025-09-30
$1.96M
淨利潤
2026-06-30
-$736.93K
2026-03-31
-$1.56M
2025-12-31
-$3.56M
2025-09-30
-$2.04M
淨利潤率
2026-06-30
--
2026-03-31
--
2025-12-31
447.63%
2025-09-30
-256.6%
每股收益
2026-06-30
$-0.03
2026-03-31
--
2025-12-31
--
2025-09-30
$-0.05
息稅折舊攤銷前利潤
2026-06-30
-$678.66K
2026-03-31
-$1.54M
2025-12-31
-$3.56M
2025-09-30
-$1.95M
有效稅率
2026-06-30
90.92%
2026-03-31
92.32%
2025-12-31
-0.01%
2025-09-30
-0.02%
項目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
營業收入
$0
$0
-$795.95K
$795.95K
營業支出
$779.52K
$1.57M
$2.19M
$1.96M
淨利潤
-$736.93K
-$1.56M
-$3.56M
-$2.04M
淨利潤率
--
--
447.63%
-256.6%
每股收益
$-0.03
--
--
$-0.05
息稅折舊攤銷前利潤
-$678.66K
-$1.54M
-$3.56M
-$1.95M
有效稅率
90.92%
92.32%
-0.01%
-0.02%
常見問題
ABVC is the ticker symbol for ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company. The stock represents ownership in a business focused on developing therapies in areas such as oncology, ophthalmology, and central nervous system disorders. Because it is a small-cap, early-stage company, ABVC's share price can be sensitive to clinical trial updates, financing news, and broader sector sentiment. The latest ABVC quote and company profile are available on the stock detail page.
Several factors can influence ABVC shares, including clinical trial results, regulatory decisions from agencies like the FDA, partnership or licensing announcements, and capital-raising activities. Because ABVC is a small-cap biopharmaceutical company, its stock may also react to changes in biotech sector sentiment, interest rates, and general market conditions. Company-specific news such as pipeline updates or financing terms often has a larger impact than broad market moves. Always check the latest ABVC disclosures for current developments.
ABVC has historically shown relatively high volatility, which is common for small-cap biopharmaceutical stocks with limited revenue and clinical-stage pipelines. Price swings can occur around trial data, financing news, and shifts in biotech sentiment. Volatility reflects both company-specific uncertainty and broader market conditions. For the latest volatility measures, such as beta or average trading range, refer to the current ABVC data displayed on the stock detail page.
Valuing ABVC is challenging because clinical-stage biopharma companies often have little or no product revenue, so traditional metrics like the P/E ratio may not be meaningful. Investors may consider cash position, pipeline progress, collaboration deals, and potential market opportunities for its drug candidates. Enterprise value, price-to-book, and comparable company analysis can also provide context. The latest ABVC valuation metrics and financial data are available on the stock detail page.
Fractional share availability for ABVC depends on the brokerage platform. Many major U.S. brokers offer fractional shares for selected stocks, allowing investors to buy a dollar amount rather than a whole share. Some platforms, however, limit fractional trading to larger companies or specific securities. To confirm whether ABVC supports fractional purchases, check your broker's current offerings or the trading details on the ABVC stock page.
ABVC is a clinical-stage biopharmaceutical company and generally does not pay dividends. Instead, it typically reinvests capital into research, development, and clinical programs. For the most accurate and current dividend information, including any special distributions if applicable, refer to the dividend section of the ABVC stock detail page. There is no regular dividend history to evaluate for this stock.